Proteflazid drops, 30 ml per bottle with a dropper.
Composition
1 mL of drops contains 1 mL of Proteflazid liquid extract (flavonoid content not less than 0.32 mg/mL, calculated as rutin, carboxylic acid content not less than 0.30 mg/mL, calculated as malic acid) from the herb Deschampsia caespitosa (Herba Deschampsia caespitosa L.) and the herb Calamagrostis epigeios (Herba Calamagrostis epigeios L.) (1:1).
Extraction solvent: 96% ethanol.
Dosage form
Drops.
Main physicochemical properties: a dark green liquid with a characteristic odor.
Pharmacotherapeutic group
Direct-acting antivirals. ATC code J05A X.
Pharmacological properties
Pharmacodynamics
The flavonoids contained in the drug inhibit the replication of DNA- and RNA-containing viruses both in vitro and in vivo. Preclinical and clinical studies have demonstrated the drug’s antiviral activity against herpes viruses, hepatitis viruses, papillomaviruses, HIV, influenza, and acute respiratory infections.
It has been demonstrated that the mechanism of direct antiviral action involves the inhibition of virus-specific enzymes—DNA and RNA polymerases, thymidine kinase, reverse transcriptase, 3CL protease, and neuraminidase.
Proteflazid inhibits the activity of the SARS-CoV-2 coronavirus 3CL protease, as confirmed by molecular docking and using an assay kit containing 3CL protease labeled with MBP (maltose-binding protein of the SARS-CoV-2 coronavirus).
Using a double-report gene assay with Renilla luciferase (which mimics the replication of the seasonal coronavirus CoV-229E), it was shown that the drug blocks it.
In preclinical in vitro studies using monkey (Vero E6) and human (A549/ACE2) cell cultures the drug’s antiviral activity against the human pandemic coronavirus SARS-CoV-2 was demonstrated, with significant inhibition of viral replication.
The drug has immunotropic properties. It protects mucous membranes by normalizing local immune parameters (lactoferrin, secretory immunoglobulin A, lysozyme, and complement component C3).
It has been established that the drug induces the synthesis of endogenous α- and γ-interferons to physiologically active levels, which increases the body’s nonspecific resistance to viral and bacterial infections.
Clinical studies have shown that when taken daily, in accordance with age-specific doses and dosing regimens, the drug has no immunotoxic effects and does not cause refractoriness (hyporeactivity) of the immune system: no suppression of alpha- and gamma-interferon synthesis is observed, which makes it possible, if necessary, to use the drug for an extended period.
The drug has antioxidant activity, inhibits free-radical processes, thereby preventing the accumulation of lipid peroxidation products and enhancing the antioxidant status of cells, reduces toxicity, promotes the body’s recovery after an infection, and aids adaptation to adverse environmental conditions.
The drug is an apoptosis modulator; it enhances the action of apoptosis-inducing substances and activates caspase-9, thereby promoting the elimination of virus-infected cells and the primary prevention of chronic diseases arising from latent viral infections.
The drug prevents disease relapses and prolongs the remission period.
Pharmacokinetics.
The drug’s active ingredients are rapidly absorbed from the gastrointestinal tract into the bloodstream, reaching peak concentrations as early as 20 minutes after administration (in vivo studies). Based on the observed kinetics, the half-life in blood plasma is approximately 2.3 hours. Bioavailability following oral administration is 80%. Elimination from the body is slow. The accumulation of active ingredients in blood cells is significantly higher than in blood plasma. The corresponding concentrations of active ingredients in the blood ensure a prolonged effect of the drug in the body and accumulation in organs and tissues as a result of their release from blood cells. These pharmacokinetic dynamics of accumulation and release of the active ingredients by blood cells necessitate twice-daily administration of the drug to achieve effective concentrations.
Indications
Treatment of diseases and prevention of relapses caused by:
- Herpes simplex viruses (types 1 and 2);
- herpes zoster and varicella-zoster viruses (Herpes Zoster, type 3);
- herpes virus type 4 (Epstein-Barr virus), in both acute and chronic active forms;
- herpes virus type 5 (cytomegalovirus).
Treatment and prevention of influenza and other acute respiratory viral infections (including pandemic influenza strains).
As part of comprehensive treatment for:
- hepatitis B and C;
- viral, bacterial, and fungal infections, as well as their co-infections (chlamydia, mycoplasma, ureaplasma, etc.);
- HIV infection and AIDS.
Etiotropic therapy for mild and moderate forms of cervical dysplasia (CIN1 and CIN2) caused by human papillomavirus (HPV) infection, including oncogenic strains.
As part of complex therapy for other forms of diseases caused by human papillomavirus infection, including oncogenic strains.
Contraindications
Hypersensitivity to any component of the drug. Gastric or duodenal ulcer.
Interactions with Other Medications and Other Types of Interactions
During clinical use, the possibility and advisability of combining Proteflazid® with antibiotics and antifungal agents for the treatment of viral-bacterial and viral-fungal diseases have been established. No adverse effects resulting from interactions with other medications have been identified.
Special Considerations for Use
In the treatment of viral hepatitis, 10–15% of patients with severe cytolytic syndrome may experience elevated aminotransferase levels 2–4 weeks after the start of treatment, and, less commonly, an increase in bilirubin levels, which lasts for 2–4 weeks and does not require discontinuation of the drug.
Patients with gastrointestinal disorders and chronic gastroduodenitis should take the medication 1.5–2 hours after a meal in the event of an exacerbation of gastroduodenitis or the onset of gastroesophageal reflux.
A transient increase in body temperature up to 38 °C does not require discontinuation of the medication. If body temperature rises, consult a doctor to rule out other possible causes.
When applying the medication topically, if a burning sensation, itching, or dryness occurs, reduce the concentration of the medication in the solution used for application.
To prevent urogenital reinfection, concurrent treatment of the sexual partner is recommended.
Use during pregnancy or breastfeeding.
Preclinical studies did not reveal any embryotoxic, teratogenic, fetotoxic, mutagenic, or carcinogenic effects. No specific studies have been conducted on the drug’s effects on the human fetus, but clinical experience with the drug during the first through third trimesters of pregnancy and during breastfeeding has not revealed any adverse effects. The decision on whether to use the drug during pregnancy or breastfeeding should be made by a physician.
Effect on reaction time when driving or operating machinery.
When used at the recommended doses, no adverse effects on the ability to perform tasks requiring special attention and quick reactions have been observed.
Directions for Use and Dosage
Shake the bottle well before use.
The medication is dispensed using a dropper. Add the required amount of the medication to water (1–2 tablespoons), and take it 10–15 minutes before a meal.
Dosage schedule for Proteflazid®, drops, depending on age
| Age (years) | Dose (drops) and frequency
per day |
| From birth to 1 year | 1 drop per day |
| 1–2 years | 1 drop twice daily |
| 2–4 years | 2 drops twice daily |
| 4–6 years | 4 drops twice a day |
| 6–9 years | 9 drops twice daily |
| 9–12 years | 10 drops twice daily |
| Children 12 years and older and adults | 12–15 drops twice daily |
The duration of treatment with Proteflazid® depends on the indications and the course of the disease.
For the treatment and prevention of recurrences of herpetic gingivostomatitis, pharyngotonsillitis, and chickenpox; for the comprehensive treatment of viral, bacterial, and fungal infections and their combinations; and to prevent viral and bacterial infections in patients with compromised immune systems, it is recommended to take the medication for 1 month.
For the treatment of herpetic eczema and herpetic vesicular dermatitis (in combination with topical application of the solution); herpetic meningitis and encephalitis; herpetic eye lesions; genital herpes; for the treatment of herpes zoster; acute and chronic active forms of Epstein-Barr virus infection; cytomegalovirus disease; papillomavirus infection (in combination with topical application of the solution)—it is recommended to take the medication for 3 months without interruption.
In cases of recurrent infections, treatment courses with this medication are conducted 1–2 times a year as recommended by a doctor.
The duration of treatment in pediatric practice is similar to that in adults. Doses are prescribed according to the patient’s age, depending on the course of the disease. Treatment is conducted under a doctor’s supervision.
As part of the comprehensive treatment of viral hepatitis B and C, HIV infection, and AIDS, it is recommended to take the medication for 6–12 months without interruption.
Treatment of hepatitis in HIV-infected patients and those with AIDS is conducted either before or after antiretroviral therapy.
For the treatment of influenza and other acute respiratory viral infections, the drug is used for 5 to 14 days, depending on the course of the disease. For prophylactic purposes, the drug is taken for 2–4 weeks at a dose equal to half the therapeutic dose. During an epidemic, treatment may be extended up to 6 weeks.
Topical use in combination with oral administration of the drug:
For the treatment of herpes simplex infections of the skin and mucous membranes, acute forms of herpes zoster, and cutaneous papillomatosis, apply the solution to the affected area 3–5 times daily. The duration of application is 10–15 minutes. To prepare the solution, dilute 1.5 mL (36–38 drops) in 10 mL of normal saline (sodium chloride solution).
Topical application should be continued until signs of skin or mucous membrane lesions disappear, but for no less than 10 days.
For primary and recurrent genital herpes, as well as papillomavirus and viral-bacterial infections of the female genital tract, vaginal tampons soaked in the solution are used. To prepare the solution, dilute 3.0 mL (72–75 drops) of the drug in 20 mL of normal saline. The exposure time for the vaginal tampons is 30–40 minutes; the procedure should be performed twice daily.
The duration of local application of vaginal tampons for genital herpes is 10 days; for papillomavirus and viral-bacterial infections of the female genital tract, it is 14 days.
Children
Proteflazid® may be used in children from birth.
Overdose
There are no known cases of overdose, but side effects may occur, particularly involving the gastrointestinal tract. Treatment is symptomatic.
In case of an overdose of Proteflazid®, seek medical attention immediately.
Side Effects
Allergic reactions: Hypersensitivity reactions may occur in individuals with hypersensitivity. Allergic reactions, including erythematous rashes and itching, may rarely occur.
Gastrointestinal system: Isolated cases of gastrointestinal disorders have been observed—epigastric pain, nausea, vomiting, and diarrhea. In patients with chronic gastroduodenitis, exacerbation of gastroduodenitis or the development of gastroesophageal reflux (reflux esophagitis) is possible.
General disorders: In rare cases, headache, general weakness, and a transient increase in body temperature up to 38 °C may occur on days 3–10 of treatment with the drug.
Laboratory parameters: During treatment of viral hepatitis, an increase in aminotransferase activity (less commonly, an increase in bilirubin levels) is observed in 10–15% of patients with severe cytolytic syndrome.
Local reactions: When applied topically, a burning sensation, itching, or dryness may occur.
If any adverse reactions occur, consult a doctor.
Shelf life
3 years.
Do not use after the expiration date printed on the package.
Storage Conditions
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze! The formation of a gel-like consistency is normal; it breaks down when shaken. Keep out of reach of children.
Packaging
Light-protective glass vials containing 10 mL, 30 mL, or 50 mL, sealed with bottle caps featuring dropper stoppers with tamper-evident seals or bottle caps featuring dropper stoppers with tamper-evident seals and child-resistant features, in a cardboard box.
Manufacturer
Ecofarm Scientific and Production Complex, LLC.
Manufacturer’s location and business address.
Ukraine, 30070, Khmelnytskyi Oblast, Shepetivka Raion, village of Ulashanivka, 116 Shevchenko Street.
Applicant
“NVK ‘Ecofarm’” LLC.
Location of the applicant.
Ukraine, 03045, Kyiv, Naberezhno-Korchuvatska St., 136-B
Similar products
Products from the same category









